You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

CLINICAL TRIALS PROFILE FOR BIVIGAM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for BIVIGAM

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT03829566 ↗ Autologous Transplant To End NMO Spectrum Disorder Withdrawn Northwestern University Phase 2/Phase 3 2019-11-01 This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term remission.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 1 of 1 entries

Clinical Trial Conditions for BIVIGAM

Condition Name

1110-0.100.10.20.30.40.50.60.70.80.911.1Devic's DiseaseNeuromyelitis OpticaNMO Spectrum Disorder[disabled in preview]
Condition Name for BIVIGAM
Intervention Trials
Devic's Disease 1
Neuromyelitis Optica 1
NMO Spectrum Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

110-0.100.10.20.30.40.50.60.70.80.911.1Neuromyelitis OpticaDisease[disabled in preview]
Condition MeSH for BIVIGAM
Intervention Trials
Neuromyelitis Optica 1
Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for BIVIGAM

Trials by Country

+
Trials by Country for BIVIGAM
Location Trials
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for BIVIGAM
Location Trials
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for BIVIGAM

Clinical Trial Phase

100.0%0-0.100.10.20.30.40.50.60.70.80.911.1Phase 2/Phase 3[disabled in preview]
Clinical Trial Phase for BIVIGAM
Clinical Trial Phase Trials
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

100.0%0-0.100.10.20.30.40.50.60.70.80.911.1Withdrawn[disabled in preview]
Clinical Trial Status for BIVIGAM
Clinical Trial Phase Trials
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BIVIGAM

Sponsor Name

trials000001111111Northwestern University[disabled in preview]
Sponsor Name for BIVIGAM
Sponsor Trials
Northwestern University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

100.0%0-0.100.10.20.30.40.50.60.70.80.911.1Other[disabled in preview]
Sponsor Type for BIVIGAM
Sponsor Trials
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

BIVIGAM: Clinical Trials, Market Analysis, and Projections

Introduction to BIVIGAM

BIVIGAM, an immune globulin intravenous (human) 10% liquid, is a crucial therapeutic agent used in the treatment of primary humoral immunodeficiency (PI) and other immune disorders. Here, we will delve into the recent clinical trials, market analysis, and future projections for BIVIGAM.

Clinical Trials Update

Pediatric Approval

In December 2023, the FDA expanded the approval of BIVIGAM to include pediatric patients aged 2 years and older with primary humoral immunodeficiency. This approval was based on the results of a prospective, open-label, single-arm study (Study 994) conducted in 16 pediatric participants aged 2 to 16 years. The study aimed to evaluate the incidence of acute serious bacterial infections (SBIs) as the primary efficacy endpoint.

  • Key Findings: No acute SBIs occurred during the mean observation period of approximately 5 months. There were no hospitalizations due to infection, and none of the patients required IV antibiotics. Trough total IgG levels were maintained above 500 mg/dL in all patients[3][4].

Study Design and Outcomes

  • Study 994: This Phase 4, multi-center study involved 16 pediatric subjects who received BIVIGAM infusions every 3 to 4 weeks. The study demonstrated that BIVIGAM was effective in preventing acute SBIs and maintaining adequate IgG levels in pediatric patients[3][4].

  • Safety Profile: The safety profile of BIVIGAM in pediatric subjects was consistent with other IGIV products and the safety profile in adults. There were no deaths or dropouts due to adverse events, and the proportion of infusions associated with adverse events was within acceptable limits[3].

Market Analysis

Global Immunoglobulin Market

The global immunoglobulin market, which includes BIVIGAM, is experiencing significant growth driven by several factors:

  • Increasing Prevalence of Immunodeficiency Disorders: The rise in primary and secondary immunodeficiencies is a major driver, increasing the demand for immunoglobulin therapies[5].

  • Geriatric Population and Hemophilic Patients: The growing geriatric population and the number of hemophilic patients also contribute to the market growth[2].

  • Technological Advancements: Improved technologies in immunoglobulin production and enhanced purification techniques are boosting the market[2].

Market Size and Projections

  • Current Market Size: The global immunoglobulin market was valued at approximately $16.45 billion in 2024[5].

  • Future Projections: The market is expected to grow at a CAGR of 4.70% from 2025 to 2033, reaching $25.77 billion by 2033[5].

  • Regional Dominance: North America currently dominates the market, accounting for 46.5% of the global share in 2024. However, other regions such as Asia Pacific and Latin America are expected to see increased adoption rates due to rising disposable income and healthcare expenditures[5].

Key Market Players

The immunoglobulin market is oligopolistic, dominated by prominent players such as Grifols, CSL, Takeda Pharmaceuticals, Baxter International, and Octapharma. These companies have a strong hold in the blood fractionation industry and play a key role in determining the cost of blood products[2].

Market Drivers and Challenges

Drivers

  • Rising Incidences of Immune Disorders: The increasing prevalence of diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia, and other autoimmune diseases is driving the market[2][5].

  • Advancements in Immunotherapy: Ongoing clinical research and innovations in immunoglobulin formulations, such as subcutaneous and intravenous delivery methods, are providing an impetus to market growth[5].

  • Growing Awareness: Rising awareness and diagnosis of autoimmune diseases have increased the usage of immunoglobulins as an effective treatment modality[5].

Challenges

  • Stringent Regulations: Government regulations toward the use of intravenous immunoglobulin products can hamper market growth[2].

  • Side Effects: The high risk of side effects associated with intravenous immunoglobulin products is another challenge[2].

Conclusion

BIVIGAM has made significant strides in clinical trials, particularly with its expanded approval for pediatric patients. The global immunoglobulin market, driven by increasing prevalence of immune disorders, technological advancements, and growing awareness, is poised for substantial growth. However, the market must navigate stringent regulations and the risk of side effects to fully capitalize on its potential.

Key Takeaways

  • Expanded Pediatric Approval: BIVIGAM is now approved for pediatric patients aged 2 years and older with primary humoral immunodeficiency.
  • Clinical Trial Success: No acute SBIs occurred in pediatric patients during the study period, and IgG levels were maintained above 500 mg/dL.
  • Market Growth: The global immunoglobulin market is projected to reach $25.77 billion by 2033, driven by rising incidences of immune disorders and technological advancements.
  • Regional Dominance: North America currently dominates the market, but other regions are expected to see increased adoption rates.
  • Challenges: Stringent regulations and the risk of side effects are key challenges for the market.

FAQs

What is BIVIGAM used for?

BIVIGAM is used for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients aged 2 years and older.

What was the primary efficacy endpoint in the pediatric study of BIVIGAM?

The primary efficacy endpoint was the incidence of acute serious bacterial infections (SBIs) during the study period.

How is BIVIGAM administered?

BIVIGAM is administered as an intravenous infusion, typically every 3 to 4 weeks.

What are the key drivers of the global immunoglobulin market?

The key drivers include the rising incidence of immune disorders, technological advancements in production and purification, and growing awareness of autoimmune diseases.

Which regions dominate the global immunoglobulin market?

North America currently dominates the market, but regions like Asia Pacific and Latin America are expected to see increased adoption rates in the future.

Sources

  1. Immune Globulin Therapy (Asceniv™, Bivigam®, Cutaquig®) - Blue Cross Blue Shield of Louisiana[1].
  2. Intravenous Immunoglobulin Market Share Report, 2033 - Allied Market Research[2].
  3. Clinical Review Memo - BIVIGAM - FDA[3].
  4. Bivigam Approved for Younger Patients With Primary Humoral Immunodeficiency - EMPR[4].
  5. Immunoglobulin Market Size, Growth & Global Report 2033 - IMARC Group[5].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.